Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics

被引:10
|
作者
Yang, An-Yin [1 ]
Liu, Hong-Li [2 ]
Yang, Yong-Feng [1 ]
机构
[1] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Liver Dis, Nanjing, Peoples R China
[2] Southeast Univ, Med Coll, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; network pharmacology; Scutellaria barbata; oral delivery; target validation; drug development; APOPTOSIS POTENTIATION; CELL-PROLIFERATION; CANCER-CELLS; COMBINATION; PROGRESSION; INHIBITION; EXPRESSION; AUTOPHAGY; WOGONIN; PATHWAY;
D O I
10.3389/fphar.2022.1072547
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Hepatocellular carcinoma is one of the most common cancers with the characteristics of invasion and high mortality. Current forms of prevention remain severe. Scutellaria barbata is widely used in traditional Chinese medicine treatment of various tumors. This study explored the mechanism of Scutellaria barbata in the treatment of hepatocellular carcinoma by network pharmacology and bioinformatics.Methods: The active ingredients of Scutellaria barbata and potential targets for the treatment of hepatocellular carcinoma were collected by network pharmacology. The protein interaction network was constructed to screen the core targets, and the association between the core targets and diseases was further verified by bioinformatics methods. Finally, the active ingredients corresponding to the targets closely related to the disease were screened for AMDE characteristics analysis. Molecular docking of drug-like ingredients with corresponding targets was performed. We used CCK-8 kit to determine the effect of active ingredients on cell proliferation.Results: 29 candidate active ingredients and 461 related targets of Scutellaria barbata were screened. A total of 8238 potential therapeutic targets for hepatocellular carcinoma were indentified. Finally, 373 potential targets for the treatment of HCC were obtained. The active ingredients: wogonin, Rhamnazin, eriodictyol, quercetin, baicalein, and luteolin, etc. The core targets were CDK1, CDK4, SRC, and E2F1. A total of 3056 GO enrichment entries were obtained, and 180 enrichment results were obtained by KEGG pathway analysis. Genes were mainly enriched in PI3K-Akt signaling pathway, IL-17 signaling pathway, TNF signaling pathway, apoptosis pathway, and hepatocellular carcinoma pathway. Molecular docking results showed that the screened compounds had strong binding ability with the corresponding target proteins. CCK8 assays showed that Rhamnazin and Luteolin suppressed the proliferation of HCC cells significantly compared with controls.Conclusion: This study revealed that the mechanism of Scutellaria barbata in the treatment of hepatocellular carcinoma may be that the active ingredients inhibit the expression of core genes and block the PI3K-AKT signaling pathway to inhibit the proliferation, and migration and induce apoptosis of cancer cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] The use of network pharmacology to investigate the mechanism of action of Scutellaria barbata in the treatment of prostate cancer
    Zhu, Wenhui
    Mao, Lili
    Yang, Ruijie
    Tong, Shijun
    Zhai, Jing
    Ding, Guanxiong
    JOURNAL OF MENS HEALTH, 2024, 20 (05) : 12 - 20
  • [2] Network-based pharmacology-based research on the effect and mechanism of the Hedyotis diffusa-Scutellaria Barbata pair in the treatment of hepatocellular carcinoma
    Hou, Changmiao
    Wen, Xiao
    Yan, Shifan
    Gu, Xiaoxiao
    Jiang, Yu
    Chen, Fang
    Liu, Yanjuan
    Zhu, Yimin
    Liu, Xiehong
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [3] Network Pharmacology and Bioinformatics Approach Reveals the Therapeutic Mechanism of Action of Baicalein in Hepatocellular Carcinoma
    Ma, Chongyang
    Xu, Tian
    Sun, Xiaoguang
    Zhang, Shuang
    Liu, Shuling
    Fan, Shuning
    Lei, Chaofang
    Tang, Feifei
    Zhai, Changming
    Li, Changxiang
    Luo, Juan
    Wang, Qingguo
    Wei, Wei
    Wang, Xueqian
    Cheng, Fafeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 2019
  • [4] Advances in the Mechanism of Luteolin against Hepatocellular Carcinoma Based on Bioinformatics and Network Pharmacology
    Han, Yunqi
    Xiao, Yunfeng
    Yu, Lei
    Chen, Jing
    Yang, Xudong
    Cui, Hongwei
    Liang, Junqing
    JOURNAL OF CANCER, 2023, 14 (06): : 966 - 980
  • [5] Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis
    Hu, Youwen
    Xiao, Yangyang
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 5693 - 5703
  • [6] EXPLORING THE MECHANISM OF ACTION OF GINSENG IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA BASED ON NETWORK PHARMACOLOGY
    Zhou, Zhaoru
    Yu, Jingyun
    Ji, Haiwei
    Sheng, Jinjin
    Ling, Rong
    Wang, Haotian
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 8 - 8
  • [7] Scutellaria barbata and Hedyotis diffusa herb pair for breast cancer treatment: Potential mechanism based on network pharmacology
    Ma, Ting-Ting
    Zhang, Gan-Lin
    Dai, Cun-Fang
    Zhang, Bo-Ran
    Cao, Ke-Xin
    Wang, Chun-Guo
    Yang, Guo-Wang
    Wang, Xiao-Min
    JOURNAL OF ETHNOPHARMACOLOGY, 2020, 259
  • [8] Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells
    Li, Yue
    Zhang, Jiongshan
    Zhang, Kun
    Chen, Yan
    Wang, Wei
    Chen, Hongjie
    Zou, Zengcheng
    Li, Yongwei
    Dai, Min
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Preliminary Study on the Mechanism of Carvacrol Regulating Hepatocellular Carcinoma Based on Network Pharmacology
    Li, Sha
    Zhao, Haixia
    Bao, Lidao
    LETTERS IN DRUG DESIGN & DISCOVERY, 2019, 16 (11) : 1286 - 1295
  • [10] Targets and Potential Mechanism of Scutellaria baicalensis in Treatment of Primary Hepatocellular Carcinoma Based on Bioinformatics Analysis
    Liu, Defu
    Wang, Zhengjun
    Zhong, Li
    Xie, Caoyu
    Huang, Xiaonan
    Zhi, Yaofeng
    Zhang, Yuzhuo
    Liang, Jiaying
    Shi, Zhenni
    Huang, Jin
    Zhang, Shuhe
    Zhang, Jin
    Ding, Fuping
    JOURNAL OF ONCOLOGY, 2022, 2022